The week in pharma: action, reaction and insight – week to November 10, 2023

By Barbara Obstoj-Cardwell. Editor

Among dealmaking news last week, US biotechs Halozyme Therapeutics and Acumen Pharmaceuticals signed a license collaboration for the use of Enhanze drug delivery for Acumen’s Alzheimer’s disease candidate ACU193. On the regulatory front, the US Food and Drug Administration (FDA) last Wednesday approved Eli Lilly’s tirzepatide, under the trade name Zepbound, as a treatment for chronic weight management, opening competition for Novo Nordisk’s already authorized Wegovy. Anglo-Swedish pharma major AstraZeneca last week reported financial result that beat expectations, a change from some other European drugmakers. Additionally, India’s Zydus Lifesciences entered into a co-promotion for its non-alcoholic steatohepatitis (NASH) drug Lipaglyn with fellow Indian firm Lupin.

New Enhanze deal for Alzheimer’s Abeta MAb